Myovant Sciences new drug for prostate cancer

Myovant Sciences has approved its first product, Orgovyx, for the treatment of advanced prostate cancer.

Orgovyx (relugolix) is a gonadotropin-releasing hormone antagonist taken orally once a day. Representatives of the Swiss company said that a new option for oral pharmacotherapy has appeared in patients with advanced prostate cancer. The drug has shown good reliable efficacy and safety, and Myovant Sciences will strive to make this drug as a new standard of treatment. As stated in terms of safety and efficacy, Orgovyx has outperformed the comparison drug leuprolide (antiandrogen therapy) in a phase 3 study involved over 900 patients with advanced prostate cancer.

The company is considering the option to bring Orgovyx to market as early as January 2021. In addition, Myovant Sciences is now testing relugolix in gynecology as a combination therapy for uterine fibroids and pain associated with endometriosis.

Source: FDA